ライフサイエンスコーパス: fixed dose

1 be either a dose proportional to weight or a fixed dose.

2 also received s.c. injections of GM-CSF at a fixed dose.

3 Shaking behavior caused by a fixed dose (2.5mg/kg) of icilin was also inhibited in a

4 ts were randomly assigned (1:1) to switch to fixed-dose 200 mg emtricitabine with 10 mg or 25 mg teno

5 Dosing schema varied and were either a fixed dose (6 [29%]) or based on body weight (10 [48%])

6 Two dosing scenarios were investigated: fixed dose (80 mg of febuxostat daily, 0.80 success rate

7 reviously demonstrated anemia advantage with fixed dose administration.

8 Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, m

9 are generally limited to a single drug at a fixed dose and frequency.

10 rubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered befo

11 heparins in many patients, are prescribed in fixed doses and do not need any coagulation monitoring i

12 farin (n=404), warfarin (n=408; 324 [79%] on fixed-dose and 84 [21%] on dose-adjusted) did not reduce

13 antially reduced residual albuminuria during fixed dose angiotensin-converting enzyme inhibition.

14 ere randomized 2:1 to receive abatacept at a fixed dose approximating 10 mg/kg by weight range, or pl

15 Paclitaxel was administered at a fixed dose, as either a 24- or 3-hour infusion on day 1,

16 .23 mg/m(2), which was converted to a 4.0 mg fixed dose based on population pharmacokinetic results.

17 e regimen of budesonide plus formoterol with fixed-dose budesonide plus formoterol and fixed-dose flu

18 formoterol maintenance and reliever therapy, fixed-dose budesonide plus formoterol, or fixed-dose flu

19 ofemoral deep vein thrombosis treated with a fixed-dose catheter thrombolysis regimen, the addition o

20 The use of fixed-dose chemotherapy is rarely justified, but the Pan

21 ouble-blind, placebo-controlled, randomized, fixed-dose clinical trial evaluating the efficacy of GSK

22 manufacturing licenses for large numbers of fixed dose combination (FDC) drugs had been issued by st

23 osterone antagonist eplerenone in 2003 and a fixed dose combination of hydralazine-isosorbide dinitra

24 Dapagliflozin (Farxiga), alone, or in the fixed dose combination with metformin (Xigduo), is an or

25 Fixed dose combination, or polypill, therapy has been sh

26 blind treatment with nebivolol and valsartan fixed-dose combination (5 and 80 mg/day, 5 and 160 mg/da

27 patasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-dose combination (FDC), an interferon-free, comple

28 At week 8, the fixed-dose combination 20 and 320 mg/day group had signi

29 ir, emtricitabine, and tenofovir alafenamide fixed-dose combination [bictegravir group] and 330 with

30 With the fixed-dose combination alone, response rates were 93% (9

31 afety of a 3-day supervised treatment of the fixed-dose combination artesunate-amodiaquine Winthrop((

32 assigned participants (1:1) to receive oral fixed-dose combination bictegravir 50 mg, emtricitabine

33 The fixed-dose combination dispersible tablet of arterolane

34 atistical comparison was between the highest fixed-dose combination dose and the highest monotherapy

35 The cross-sectional FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular

36 med to further assess safety and efficacy of fixed-dose combination emtricitabine with tenofovir alaf

37 ears and older receiving regimens containing fixed-dose combination emtricitabine with tenofovir diso

38 nucleotide polymerase inhibitor, as a single fixed-dose combination for 12 weeks.

39 terol, added to fluticasone propionate, in a fixed-dose combination in children.

40 ered once daily with the abacavir/lamivudine fixed-dose combination in treatment-naive human immunode

41 omes can be conveniently treated with triple fixed-dose combination inhaler therapy with an inhaled c

42 Nebivolol and valsartan fixed-dose combination is an effective and well-tolerate

43 We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12

44 ty-assured generic medicines, development of fixed-dose combination medicines, and promotion of adher

45 The use of fixed-dose combination nucleoside reverse-transcriptase

46 underwent randomization for treatment with a fixed-dose combination of 180 mg of pyronaridine and 60

47 dolutegravir with matching placebo plus the fixed-dose combination of 200 mg emtricitabine and 25 mg

48 ty of QVA149 (indacaterol/glycopyrrolate), a fixed-dose combination of a long-acting beta2-agonist (i

49 We assessed the efficacy and safety of a fixed-dose combination of a vasodilating beta blocker (n

50 The efficacy and safety of fixed-dose combination of AM and PQP was comparable to A

51 The fixed-dose combination of any two antihypertensive drugs

52 A fixed-dose combination of arterolane maleate (AM), a new

53 The fixed-dose combination of bictegravir, emtricitabine, an

54 ents received twice-daily treatment with the fixed-dose combination of daclatasvir (30 mg), asunaprev

55 Patients received a twice-daily fixed-dose combination of daclatasvir, 30 mg; asunaprevi

56 Patients were given an oral, once-daily, fixed-dose combination of EBR/GZR 50 mg/100 mg for 12 we

57 The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtr

58 INTERPRETATION: The fixed-dose combination of elvitegravir, cobicistat, emtr

59 inetics, and efficacy of this single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtr

60 eive treatment for 8, 12, or 16 weeks with a fixed-dose combination of grazoprevir, ruzasvir, and upr

61 ed for smoking status) to once-daily QVA149 (fixed-dose combination of indacaterol 110 mug and glycop

62 Fixed-dose combination of isosorbide dinitrate and hydra

63 n SBP on the effectiveness of treatment with fixed-dose combination of isosorbide dinitrate and hydra

64 We previously reported that the fixed-dose combination of isosorbide dinitrate and hydra

65 Fixed-dose combination of isosorbide dinitrate/hydralazi

66 ver before treated for HCV were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbu

67 INTERPRETATION: The rate of cure with a fixed-dose combination of ledipasvir-sofosbuvir for pati

68 The phase 3 ION studies evaluated a fixed-dose combination of ledipasvir/sofosbuvir +/- riba

69 ncluding lopinavir (LPV) ISNP granules and a fixed-dose combination of LPV/ritonavir (RTV) ISNP granu

70 termittent preventive treatment (IPT) with a fixed-dose combination of mefloquine-artesunate (MQAS) o

71 s to develop a nanotechnology to formulate a fixed-dose combination of poorly water-soluble drugs in

72 sis were randomly assigned to groups given a fixed-dose combination of SOF and LDV, with RBV (n = 9)

73 rhosis were randomly assigned to an all-oral fixed-dose combination of sofosbuvir (400 mg) and velpat

74 atients with decompensated cirrhosis given a fixed-dose combination of sofosbuvir and velpatasvir wit

75 The fixed-dose combination of sofosbuvir plus ledipasvir was

76 These findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or

77 y, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg

78 A fixed-dose combination of sofosbuvir-velpatasvir-voxilap

79 itive participants to trial clinics for ART (fixed-dose combination of tenofovir, emtricitabine, and

80 sess the efficacy and safety of an all-oral, fixed-dose combination of the hepatitis C virus NS5A inh

81 and safety of an interferon-free regimen--a fixed-dose combination of the nucleotide polymerase inhi

82 nofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir

83 regimens, including combinations of DAAs and fixed-dose combination pills.

84 he growing body of clinical evidence for the fixed-dose combination regimen of elbasvir plus grazopre

85 ive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or sofosbu

86 andomly (1:1) to receive 12 or 24 weeks of a fixed-dose combination tablet containing ledipasvir and

87 merase inhibitor sofosbuvir in a once-daily, fixed-dose combination tablet for 12 weeks, ledipasvir-s

88 Patients were given a fixed-dose combination tablet of 90 mg ledipasvir and 40

89 ive and 22 treatment experienced) received a fixed-dose combination tablet of 90 mg of ledipasvir and

90 All patients received the fixed-dose combination tablet of LDV-SOF once-daily plus

91 ype 3 were randomly assigned to groups given fixed-dose combination tablet of ledipasvir and sofosbuv

92 The first received a fixed-dose combination tablet of ledipasvir-sofosbuvir (

93 e III studies, treatment with the once-daily fixed-dose combination tablet of ledipasvir/sofosbuvir (

94 were randomized to receive treatment with a fixed-dose combination tablet of sofosbuvir-velpatasvir-

95 io to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 weeks, l

96 grazoprevir 100 mg plus elbasvir 50 mg in a fixed-dose combination tablet once daily for 12 weeks.

97 NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tablet or matching placebo for 12

98 ceived sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once

99 th trimethoprim-sulfamethoxazole in a single fixed-dose combination tablet), 12 weeks of fluconazole,

100 Is fixed-dose combination therapy (polypill) that combines

101 Treatment with ICS/LABA fixed-dose combination therapy appeared to perform as we

102 sterol-lowering, antithrombotic therapy, and fixed-dose combination therapy.

103 emtricitabine and tenofovir alafenamide as a fixed-dose combination to dolutegravir administered with

104 emtricitabine and tenofovir alafenamide as a fixed-dose combination versus coformulated dolutegravir,

105 Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a s

106 olving children with asthma, salmeterol in a fixed-dose combination with fluticasone was associated w

107 to assess the efficacy and safety of SOF/LDV fixed-dose combination without RBV in patients with HCV

108 d sofosbuvir-velpatasvir (400 mg/100 mg in a fixed-dose combination) plus GS-9857 (100 mg) once daily

109 de reverse transcriptase inhibitor (NRTI) in fixed-dose combination.

110 drug combination in a larger population as a fixed-dose combination.

111 irus (HCV) genotype 1 and 4 infections, as a fixed-dose combination.

112 irus (HCV) genotype 1 and 4 infections, as a fixed-dose combination.

113 e, zidovudine, or abacavir as dual or triple fixed-dose-combination paediatric tablets with lamivudin

114 Fixed dose combinations (FDC) with the advantage of once

115 LAMA/LABA fixed dose combinations (FDCs) provide the convenience o

116 arisons were also significant, favouring the fixed-dose combinations (all p<0.0001).

117 The use of fixed-dose combinations (FDC) has been shown to improve

118 The use of fixed-dose combinations (FDCs) improves adherence in sev

119 rst-line treatment for HIV, and coformulated fixed-dose combinations are preferred to facilitate adhe

120 Fixed-dose combinations could reduce pill burdens and co

121 Fixed-dose combinations have shown a positive effect on

122 lability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, t

123 Procurement of generic fixed-dose combinations increased from 33.3% (95% CI, 33

124 However, development of fixed-dose combinations of poorly water-soluble drugs fo

125 s kind of novel nanotechnology for pediatric fixed-dose combinations of poorly water-soluble drugs.

126 stable, and flexible pediatric granules for fixed-dose combinations that can be used as sachets and

127 Fixed-dose combined I/H significantly reduced mortality

128 e of external-beam radiation with concurrent fixed-dose continuous-infusion doxorubicin followed by s

129 We tested the effects of 4-week fixed-dose daily adjunctive modafinil (MOD) 200 mg, in a

130 of sertraline daily, or placebo in a 6-week fixed-dose, double-blind, double-dummy, parallel-group,

131 e-of-three in drug co-prescription or making fixed-dose drug combination.

132 Patients receiving fixed-dose ECT were more likely to have an antidepressan

133 With its safety advantages, fixed-dose emtricitabine with tenofovir alafenamide has

134 The MTD of cediranib was 12 mg/m(2)/d (adult fixed dose equivalent, 20 mg).

135 semaglutide (doses reached after following a fixed dose-escalation regimen) or once-daily insulin gla

136 EC-Asnase, administered as a 25,000 IU/m(2) fixed dose (FD) or individualized dose (ID) starting at

137 y, fixed-dose budesonide plus formoterol, or fixed-dose fluticasone plus salmeterol for 6 months.

138 th fixed-dose budesonide plus formoterol and fixed-dose fluticasone plus salmeterol for 7 months.

139 ponse duration of low-dose rituximab (100 mg fixed dose for 4 weekly infusions) together with a short

140 rely justified, but the Panel does recommend fixed dosing for a few select agents.

141 or placebo given at 0, 24, and 48 h, with a fixed-dose furosemide regimen as background therapy.

142 Oral, once-daily, fixed-dose grazoprevir 100 mg/elbasvir 50 mg for 12 week

143 bil at 12 weeks was 200 (SD 71) ng/mL in the fixed-dose group and 318 (129) ng/mL in the pharmacokine

144 e 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg t

145 Fixed-dose I/H improved heart failure outcomes in both m

146 stically significant decreases in the use of fixed-dose ICS-LABA agents in children (-0.98 percentage

147 pen-label noninferiority study that compared fixed-dose idraparinux with adjustable-dose oral vitamin

148 usted doses may be a better alternative to a fixed dose in future studies.

149 and angiotensin II receptor antagonists) in fixed doses in which data on headache were reported.

150 oterol maintenance and reliever therapy with fixed-dose inhaled corticosteroid/long-acting beta2-agon

151 % women) were randomly assigned to receive a fixed-dose intravenous bolus, followed by a 72-hour infu

152 bsequent cohorts of patients were treated at fixed dose levels of 0.2 mg, 0.4 mg, or 0.7 mg.

153 for 7 days followed by a long-term decreased fixed dose long term can be considered.

154 an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromb

155 n with CS maintained up to 6 months, Tac and fixed-dose MMF (2 g/d) (arm B).

156 The fixed-dose, modified rheumatoid arthritis protocol for r

157 Once-daily dolutegravir in combination with fixed-dose NRTIs represents an effective new treatment o

158 The fixed dose of 1,400 mg SC rituximab predicted by using s

159 Stage 1 data predicted that a fixed dose of 1,400 mg SC rituximab would result in a se

160 In phase 2, 20 patients received a fixed dose of 1000 mg (days 1, 8, and 15 of cycle 1; day

161 -intensified treatment with (131)I-MIBG at a fixed dose of 11.1 GBq (300 mCi) per cycle is safe and o

162 by slow intravenous injection, followed by a fixed dose of 15 000 IU/m(2) bleomycin by intravenous in

163 challenged on day 0, 14 and 28 with a single fixed dose of 2.5 grams of the following (random order):

164 e, 136 millicoulombes [mC]), or RUL ECT at a fixed dose of 403 mC.

165 Children with MDS received a fixed dose of 5 mg/m(2)/dose.

166 ients were randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine.

167 5-AZA was administered subcutaneously at a fixed dose of 75 mg/m(2) daily for 7 days.

168 Use of an empiric fixed dose of 750 mg of daptomycin is predicted to achie

169 .225, 0.45, 0.9, or 1.8 mg per kilogram or a fixed dose of 80 mg).

170 Gemcitabine was given as a fixed dose of 800 mg/m(2) on days 1 and 8 every 3 weeks.

171 DLT was not observed with a fixed dose of 85 mg/m2 given every 2 weeks.

172 ent in which infected fish were exposed to a fixed dose of a common trematode parasite.

173 requiring drug therapy and they both used a fixed dose of a single statin.

174 The benefit of lipid lowering with a fixed dose of a statin appeared to be similar regardless

175 Once-monthly infusion of a fixed dose of abatacept, approximately 10 mg/kg of body

176 ion of CTLA-4-deficient cells responded to a fixed dose of Ag compared with CTLA-4-expressing cells,

177 We examined whether a fixed dose of both isosorbide dinitrate and hydralazine

178 ed that increasing amounts of SAM added to a fixed dose of BUP resulted in dose-dependent reductions

179 Fifteen patients were treated with a fixed dose of carboplatin (area under the curve [AUC] 5)

180 S that were inhibited by pretreatment with a fixed dose of clonidine (0.15 mg/kg, s.c.).

181 hyperthermia and hyperactivity induced by a fixed dose of cocaine (15 mg/kg, i.p.).

182 A group of 54 patients were treated with a fixed dose of decitabine (15 mg/m(2) by IV daily for 10

183 th total body irradiation (TBI) were given a fixed dose of donor T cells (HSCT step 1), followed by c

184 ng doses of GGTI in conjunction with a high, fixed dose of FTI causes a dose-dependent inhibition of

185 In the context of CY tolerization, a high, fixed dose of haploidentical T cells was associated with

186 No fixed dose of IL-3 determined the threshold below which

187 r stage IV melanoma were randomly assigned a fixed dose of ipilimumab of either 10 mg/kg (n=73), 3 mg

188 ntricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or p

189 The addition of a fixed dose of isosorbide dinitrate plus hydralazine to s

190 When a fixed dose of LPS was used (5 microg/mouse), db/db mouse

191 ss device using a dose of 180 mg/m2/d with a fixed dose of oral L at 5 mg/m2/d for 21 out of 28 days.

192 ere evaluated with (ADEP) or without (ADE) a fixed dose of PSC-833.

193 In conclusion, a fixed dose of riluzole (100 mg/day) did not show adjunct

194 umab, coadministration of trastuzumab with a fixed dose of T-DM1 at 3:1 and 8:1 ratios dramatically i

195 ng doses of ipilimumab in combination with a fixed dose of the PSA-Tricom vaccine.

196 lfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz a

197 Four subjects were inoculated with fixed doses of 35000HP (101 CFU or 130 CFU) at three sit

198 5 volunteers were inoculated at 3 sites with fixed doses of 35000HP on one arm and at 3 sites with va

199 fety of pharmacological prevention with low, fixed doses of anticoagulant drugs, prophylaxis remains

200 se-contingent access to conditioned cues and fixed doses of cocaine.

201 of 40, 50, 60, and 80 mg/m(2) was given with fixed doses of cyclophosphamide, vincristine, and predni

202 daunorubicin (DNR) and etoposide (ETOP) and fixed doses of cytarabine were evaluated with (ADEP) or

203 response technology, to receive one of three fixed doses of deutetrabenazine (12 mg/day, 24 mg/day, o

204 ss the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel vesicular monoam

205 day for 3 days), coupled with our historical fixed doses of fludarabine and rituximab (BFR), as a non

206 ophrenia randomly assigned to four different fixed doses of haloperidol decanoate and treated for 1 y

207 Regimens that infuse fixed doses of insulin with high rates of glucose are us

208 andomly assigned in a 3:1:1 ratio to receive fixed doses of investigational drug, placebo, or haloper

209 s study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafax

210 1.45% [CI, -1.80% to - 1.10%]) compared with fixed doses of oral agents but much less when compared w

211 nd treatment of either placebo or one of two fixed doses of oral, once-daily bitopertin (10 or 20 mg

212 This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalize

213 Higher fixed doses of peginterferon alfa-2a (270 microg/week) a

214 revention, some have advocated administering fixed doses of statins based on a person's estimated net

215 zumab who were switched directly to 8-weekly fixed dosing of aflibercept without a loading phase.

216 of 0.4 mg/m(2)/d to 16 mg/m(2)/d and 25 mg/d fixed dosing, of which 67 were assessable for toxicity.

217 rch 5, 2015, we enrolled 150 patients in the fixed-dose omecamtiv mecarbil group and 149 in the pharm

218 as a significant increase in the impact of a fixed dose on extracellular dopamine, indicating that ne

219 it of warfarin randomly assigned patients to fixed-dose or dose-adjusted warfarin groups.

220 ponse system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4.5 mg [target dose],

221 All participants received the available fixed-dose oral formulation of elvitegravir 150 mg, cobi

222 large clinical trials have demonstrated that fixed-dose oral ximelagatran, 36 mg twice daily, adminis

223 Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar

224 Fixed-dose orbofiban failed to reduce major cardiovascul

225 A double-blind, placebo-controlled, fixed-dose, parallel-group clinical trial was used.

226 The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period.

227 ridol for 14 weeks (an 8-week escalation and fixed-dose period followed by a 6-week variable-dose per

228 s in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) an

229 vels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27

230 niazid should also be combined into a single fixed-dose pill, along with pyridoxine (vitamin B6), tha

231 se heterogeneity, gamma irradiation (using a fixed dose prescription) appears to deliver a sufficient

232 These include new combination fixed-dose products, which may allow for greater flexibi

233 A fixed-dose protocol provided well-controlled INR only in

234 nts was simulated for 5 warfarin protocols-a fixed-dose protocol, a clinically guided protocol, and 3

235 Fixed-dose pyronaridine-artesunate was efficacious in th

236 etry-guided RAI therapy may be preferable to fixed-dose RAI treatment strategies in older patients wi

237 ery using pharmacokinetic principles such as fixed dose rate (FDR) infusion.

238 Gemcitabine/cisplatin, fixed dose rate gemcitabine, gemcitabine/docetaxel, and

239 tastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower d

240 Prolonged-infusion gemcitabine at a fixed dose rate of 10 mg/m(2)/min for 12 hours with 12 m

241 nd toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, doceta

242 Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have

243 Fixed-dose rate gemcitabine plus docetaxel achieves obje

244 At the fixed-dose rate of 10 mg/m(2)/min, gemcitabine could be

245 ng the duration of gemcitabine infusion at a fixed-dose rate of 10 mg/m(2)/min.

246 tabine was infused for up to 18 hours at the fixed-dose rate.

247 uld be studied with pharmacologically guided fixed dose-rate infusion.

248 Fixed-dose-rate gemcitabine and docetaxel achieved high

249 The combination of fixed-dose-rate gemcitabine and docetaxel has become an

250 Fixed-dose-rate gemcitabine and docetaxel is a reasonabl

251 For patients with disseminated disease, fixed-dose-rate gemcitabine plus docetaxel is an appropr

252 Providers noted the inflexibility of the fixed dose regimen, with dosages sometimes inappropriate

253 A fixed-dose regimen of apixaban alone was noninferior to

254 on and cirrhosis who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and becl

255 received 12 weeks of treatment with the oral fixed-dose regimen of daclatasvir, asunaprevir, and becl

256 A fixed-dose regimen of rivaroxaban alone was noninferior

257 A fixed-dose regimen of rivaroxaban, an oral factor Xa inh

258 he level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict d

259 g to a single inhaler regimen (SMART) with a fixed-dose regimen with salbutamol as reliever ('Standar

260 ibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended tr

261 gned in a 1:1 ratio to the SMART or standard fixed-dose regimen.

262 5 or 10 mg amlodipine daily for 4 weeks in a fixed-dose regimen.

263 Results using fixed-dose regimens showed a low incidence of rejection

264 , could improve safety compared to the early fixed-dose regimens.

265 omized to full-dose CsA (microemulsion) plus fixed-dose SRL (2 mg/day; group A, n=97) or reduced-dose

266 n (ACC/AHA) cholesterol guidelines recommend fixed-dose statin therapy for those at risk and do not r

267 No trial directly compared titrated vs fixed-dose statins, and there were no clear differences

268 e-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with bipolar I disord

269 hm to intravenous rituximab (375 mg/m(2)) or fixed-dose subcutaneous rituximab (1400 mg), stratified

270 okinetic non-inferiority of 3 week cycles of fixed-dose subcutaneous rituximab versus standard intrav

271 The study regimen consisted of a fixed-dose tablet containing darunavir 800 mg, cobicista

272 To evaluate the efficacy and safety of a fixed-dose tablet containing sumatriptan succinate and n

273 release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB16), or matching pla

274 release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB32), sustained-relea

275 12 weeks followed by once daily combination fixed-dose tablets of 90 mg ledipasvir and 400 mg sofosb

276 The visual and anatomic improvements after fixed dosing through week 24 and PRN dosing with monthly

277 andomized, double-blind, placebo-controlled, fixed-dose trial using a sequential parallel comparison

278 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis ad

279 ; and regimen C (to evaluate the safety of a fixed dose two-thirds the MTD of regimen A given every 2

280 Fixed-dose unmonitored treatment with dabigatran etexila

281 mized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-int

282 nd with dose-adjusted warfarin compared with fixed-dose warfarin (16 vs 7, p=0.09).

283 However, compared with fixed-dose warfarin (n=471), dose-adjusted warfarin (n=4

284 ng chemotherapy through CVCs to no warfarin, fixed-dose warfarin 1 mg per day, or dose-adjusted warfa

285 The fixed dose was prescribed at 2 mm from the centerline of

286 During fixed dosing (weeks 12-52) all exudative features showed

287 t that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including

288 doxaban, and rivaroxaban are administered in fixed doses without anticoagulant monitoring.

289 ban, rivaroxaban, and edoxaban) and given in fixed doses without coagulation monitoring.

290 asugrel, and ticagrelor, are administered in fixed doses without laboratory monitoring.

291 ction and the capacity to be administered in fixed doses without routine coagulation monitoring, NOAC

292 cal care because they can be administered in fixed doses without routine coagulation monitoring.

293 acological basis for their administration in fixed doses without routine coagulation monitoring.

294 icians should continue to prescribe NOACs in fixed doses without routine monitoring.

295 l fibrillation were developed to be given in fixed doses without the need for the routine monitoring

296 coagulant agents that can be administered in fixed doses, without laboratory monitoring and dose adju

297 et international normalized ratio 2 to 3) or fixed-dose ximelagatran 36 mg twice daily.

298 For prophylaxis of venous thromboembolism, fixed-dose ximelagatran started the morning after total

299 V), have compared the efficacy and safety of fixed-dose ximelagatran without anticoagulation monitori

300 nofovir-emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus ef